Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735997 | 0.85 | IKBKB (0.48) | CYP2C9PPARGEPHX2 | |
| SCHEMBL215875 | 0.85 | SMN1; SMN2 (0.45) | CYP2C9SLC5A2TSHRGAASLC5A1 | |
| SCHEMBL215242 | 0.84 | POLB (0.51) | PPARGSLC5A2EPHX2 | |
| SCHEMBL406980 | 0.81 | SLC5A2 (0.43) | CYP2C9SLC5A2TSHRGAATDP1 | |
| SCHEMBL215073 | 0.80 | PTGDR2 (0.43) | CYP2C9 | |
| SCHEMBL407427 | 0.80 | SMN1; SMN2 (0.45) | MTHFD2SLC5A2TSHRGAASLC5A1 | |
| SCHEMBL214943 | 0.79 | SCD (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL1078847 | 0.78 | PTGDR2 (0.42) | CYP2C9PPARGTSHREPHX2GAA | |
| SCHEMBL216737 | 0.77 | KCNN4 (0.45) | SLC5A2 | |
| SCHEMBL406979 | 0.76 | HTR1A (0.58) | SLC5A2TSHRTDP1SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | claimed |
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | EGLN1 446/4885CYP2C9 631/4885PPARG 159/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | EGLN1 446/4885CYP2C9 631/4885PPARG 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.